BCAX
Bicara Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.64
+0.22%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$22.76
From 52W high−25.53%
Volume924089.00
Market cap$1.50B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$22.76
From 52W high
−25.53%
Volume
924089.00
Market cap
$1.50B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.4x
P/E (TTM)
—
RSI (14)
40.2
MomentumView details →
1D Return
+0.22%
YTD Return
+33.45%
SummaryUpdated Jun 1, 2026
Bicara Therapeutics Inc. (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Boston, Massachusetts. The company operates as a subsidiary of Biocon Limited, a major Indian biopharmaceutical company. Bicara focuses on developing innovative bifunctional antibody therapies specifically designed to treat solid tumors, representing a novel approach in cancer treatment that combines two therapeutic mechanisms into a single drug molecule.
Similar companies
Latest newsMore news →
Bicara Therapeutics initiated the FORTIFI-FLEX trial, a pivotal Phase III study, and outlined an interim analysis timeline for mid-2027.40d agoBicara Therapeutics announced leadership changes during its Q2 2026 earnings call.40d agoJeremy Bender was appointed as a Class I Director of the Board of Directors and a member of the Audit Committee and Launch Readiness Committee of Bicara Therapeutics Inc., effective July 28, 2026.55d ago